High Burden of ARFID Symptoms in Adults with Disorders of Gut–Brain Interaction: A Population-Based Study Signals Need for Routine Screening

High Burden of ARFID Symptoms in Adults with Disorders of Gut–Brain Interaction: A Population-Based Study Signals Need for Routine Screening

A 2023 population survey of 4,002 adults in the UK and US found that positive screens for avoidant/restrictive food intake disorder (ARFID) were common among people with disorders of gut–brain interaction (DGBI) and associated with greater health burden, underweight, poorer quality of life, and higher healthcare use.
Two-Year 40 Hz Audiovisual Stimulation in Mild Alzheimer’s: Safety, EEG Entrainment, and Early Biomarker Signals

Two-Year 40 Hz Audiovisual Stimulation in Mild Alzheimer’s: Safety, EEG Entrainment, and Early Biomarker Signals

An open-label two-year extension in five patients with mild Alzheimer's disease found daily 1‑hour 40 Hz audiovisual stimulation to be safe, produced sustained EEG gamma entrainment in late‑onset cases, and was associated with smaller cognitive decline and reductions in plasma pTau217 in two participants, warranting controlled trials.
Heat and Dehydration Increase Carbohydrate Use During Endurance Exercise — Heat Is the Dominant Driver

Heat and Dehydration Increase Carbohydrate Use During Endurance Exercise — Heat Is the Dominant Driver

A 2025 systematic review and meta-analysis found that endurance exercise in the heat increases carbohydrate oxidation and muscle glycogen use; dehydration amplifies this effect principally when combined with heat. Findings inform fueling and hydration strategies for athletes and at-risk populations.
Electroacupuncture Shortens Postoperative Ileus After Laparoscopic Gastrectomy: Translating a Multicenter RCT into Clinical Practice

Electroacupuncture Shortens Postoperative Ileus After Laparoscopic Gastrectomy: Translating a Multicenter RCT into Clinical Practice

A multicenter randomized trial shows electroacupuncture (EA) reduces time to first flatus and defecation and lowers prolonged POI after laparoscopic gastrectomy. Mechanistic plausibility, ERAS integration, and implementation challenges are discussed with priorities for future trials.
Indole-3-Propionic Acid Bridges Gut Dysfunction and Diabetic Retinopathy — A Biomarker and Therapeutic Avenue

Indole-3-Propionic Acid Bridges Gut Dysfunction and Diabetic Retinopathy — A Biomarker and Therapeutic Avenue

A Gut 2025 study identifies microbially produced indole-3-propionic acid (IPA) as a protective metabolite linking restored intestinal tryptophan handling to prevention of diabetic retinopathy in mice and associates low serum IPA with retinopathy in people with type 2 diabetes.
Where Are People with Chronic Hepatitis B Lost? Global review shows major gaps after diagnosis — especially outside specialist care

Where Are People with Chronic Hepatitis B Lost? Global review shows major gaps after diagnosis — especially outside specialist care

A global systematic review (110 cohorts, 50 countries) found substantial attrition across the hepatitis B care cascade: low rates of treatment eligibility assessment and antiviral initiation in primary/community models, poor retention particularly among untreated patients, and only ~73% viral suppression on therapy in specialist settings.
Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type 2 diabetes trials and a manageable hyperkalemia signal.
Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑naïve patients and outperformed available clinical decision support tools.